Move to topTop
May 16, 2022
TOKYO, JAPAN – May 16, 2022 – Terumo Corporation (TSE: 4543) today announces that the indication for the Dexcom G6 CGM System has changed in Japan as of  May 10, 2022. With this new indication, the Dexcom G6 CGM System will be the only real-time continuous glucose monitoring system (RT-CGM) in Japan that can be used principally for day-to-day management of blood glucose levels without the adjunctive use of a blood glucose meter.

The Dexcom G6 CGM System is a RT-CGM developed and manufactured by Dexcom, Inc. Terumo holds the exclusive distribution agreement rights to distribute this product in Japan, and it has been available for Japanese patients with diabetes since 2021. Users attach a small wearable sensor to the abdomen or other parts of the body so that glucose values are continuously measured and automatically transmitted every five minutes to a receiver or a smartphone with a dedicated app installed. Dexcom G6 CGM System users can constantly check their real-time glucose values and trends with a visualized graph. The system can also notify users when blood glucose values fall outside the target, as well as alert users when a severe hypoglycemic event is predicted.

Previously in Japan the indication for Dexcom G6 CGM system was limited to “assisting” blood glucose meters. As such, a blood glucose meter was required for day-to-day diabetes management such as adjusting the amount of insulin dozes. With the change in indication, a blood glucose meter is only required “when necessary” and the Dexcom G6 CGM system can be utilized for users to make everyday treatment decisions. 

Yoshiya Kikawa, Division President of Terumo’s Life Care Solution Division, Medical Care Solutions Company comments, “With this new indication we hope more patients will be able to manage their blood glucose value better and reduce the risk of diabetic complications”.

Terumo will continue to strive to improve the quality of life of patients and advance medical systems based on its Group Mission of "Contributing to Society Through Healthcare”. 
Dexcom G6 CGM System
Dexcom G6 CGM System
 
 

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.